An observational study in Upper Gastrointestinal Cancer, sponsored by Bristol-Myers Squibb. Completed at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-04-12.
Sponsored by Bristol-Myers Squibb · Observational
The purpose of this observational study is to describe the demographics, and disease characteristics of participants with metastatic upper gastrointestinal cancer, along with the treatment characteristics of these patients when treated with nivolumab.
778 studies on the registry are indexed under Gastrointestinal Neoplasms; 230 are open to participants now.
This study's enrollment of 700 is above the median of 197 across 176 observational studies indexed under Gastrointestinal Neoplasms.
Browse Gastrointestinal Neoplasms studies →Bristol-Myers Squibb is the lead sponsor of 1,538 studies on the registry; 116 are open to participants now.
Of its 429 completed or terminated interventional studies of FDA-regulated products, 223 (52%) have results posted.
Counted across the registry records on this site, refreshed daily.
The study population is comprised of individuals diagnosed with HER2 negative, unresectable, advanced or metastatic gastric cancer, gastroesophageal junction cancer or esophageal adenocarcinoma (GC/GEJC/EAC) that participated in the Bristol-Myers Squibb Patient Support Program (PSP) in Canada, GEORgiA PSP (GastroEsophageal Opdivo in non-Resectable, advanced or metastatic Adenocarcinoma)
Exclusion Criteria:
Drug: Nivolumab
As per product label
Particpant sociodemographics
Time frame: Baseline
Participant Eastern Cooperative Oncology Group (ECOG) score
Time frame: Baseline
Participant HER2 status
Time frame: Baseline
Participant comorbidities
Time frame: Baseline
Participant tumour location
Time frame: Baseline
Participant treatment history
Time frame: Baseline
Initial nivolumab dosage prescribed to participants
Time frame: Index date
Number of nivolumab treatments received by participants
Time frame: Up to 75 weeks
Planned combination chemotherapy treatment
Time frame: Index date
Nivolumab treatment initiation date
Time frame: Index date
Nivolumab dosage modification
Time frame: Up to 75 weeks
Participant treatment duration
Time frame: Up to 75 weeks
Reason for participant discharge
Time frame: Up to 75 weeks
Participant adverse events (AEs)
Time frame: Up to 75 weeks
Management of participant adverse events (AEs)
Time frame: Up to 75 weeks
Plan to share: No
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Bristol-Myers Squibb